Pancrelipase delayed-release capsules - AbbVie

Drug Profile

Pancrelipase delayed-release capsules - AbbVie

Alternative Names: CREON; Lipacreon; SA-001

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Solvay Pharmaceuticals
  • Developer Abbott Laboratories; AbbVie; Eisai Co Ltd
  • Class Pancreatic enzymes
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Exocrine pancreatic insufficiency

Most Recent Events

  • 04 Sep 2013 AbbVie, Aptalis Pharma and Janssen Research and Development initiate a porcine-virus safety trial in Cystic Fibrosis (NCT01858519)
  • 31 May 2013 AbbVie announces market availability of CREON® (36 000 lipase units) for Exocrine pancreatic insufficiency in USA
  • 31 Mar 2013 US FDA approves IND application for additional strength capsules (36 000 lipase units) for Exocrine pancreatic insufficiency
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top